Physician profile
Benjamin Weinberg
NPI 1598064941
$325,574.57
in general payments reported to CMS, 2019-2025
35 companies · $67K in 2025
The $67K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $38K · 2021: $26K · 2022: $21K · 2023: $65K · 2024: $34K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $117K · Consulting Fee: $30K · Travel and Lodging: $16K · Food and Beverage: $4,349 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116,532.34 |
| Consulting Fee | $29,814.27 |
| Travel and Lodging | $15,839.88 |
| Food and Beverage | $4,349.20 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $63,767.15 | 2019-2025 | Sir-Spheres Microspheres |
| Jazz Pharmaceuticals INC. | $57,098.58 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $50,459.17 | 2019-2022 | |
| Seagen INC. | $46,728.08 | 2022-2023 | Tukysa |
| Taiho Oncology, INC. | $36,601.12 | 2019-2023 | |
| Lilly USA, LLC | $17,108.55 | 2019-2025 | Cyramza |
| Pfizer INC. | $11,300.64 | 2024-2025 | |
| Regeneron Pharmaceuticals, INC. | $7,442.66 | 2024 | Libtayo |
| Foundation Medicine, INC. | $7,096.01 | 2022-2023 | |
| Partner Therapeutics, INC. | $7,046.98 | 2025 | Bizengri |
| Novartis Pharmaceuticals Corporation | $5,076.25 | 2021 | |
| Boehringer Ingelheim International Gmbh | $4,384.41 | 2019 | |
| Daiichi Sankyo INC. | $4,325.00 | 2021-2022 | |
| Array Biopharma INC | $2,048.02 | 2022-2025 | Braftovi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,740.00 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $1,386.00 | 2021 | |
| Caris Mpi, INC. | $450.00 | 2025 | Mi Cancer Seek |
| Exelixis INC. | $328.38 | 2024-2025 | Cabometyx |
| Intera Oncology, INC | $281.37 | 2024 | Intera |
| Ipsen Biopharmaceuticals, INC | $218.34 | 2019-2023 | Onivyde |
| G1 Therapeutics, INC. | $182.41 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $176.09 | 2019-2023 | |
| Immunocore Limited | $142.37 | 2023 | Kimmtrak |
| Beigene USA, INC. | $65.50 | 2020-2022 | |
| Janssen Research & Development, LLC | $37.53 | 2025 | |
| Tersera Therapeutics LLC | $35.26 | 2025 | Xermelo |
| Angiodynamics, INC. | $31.96 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.74 | 2022 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Weinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.